RT Conference Proceedings T1 SARS-COV-2 INFECTION AND IT VACCINATION IN AUTOINMUNE DISEASE-ASSOCIATED INTERSTICIAL LUNG DISEASE A1 Studer, A. Garcia A1 Rojas-Gimenez, M. A1 Feijoo, M. Velloso A1 Romero-Barco, C. M. A1 Godoy-Navarrete, F. A1 Mena-Vazquez, N. K1 Área de Gestión Sanitaria Sur de Sevilla AB Background: Intersticial lung disease (ILD) is a common condition in patientswith systemic autoinmune diseases (SAI) that is characterized by increasedmorbility and mortality. Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has posed huge challenges worldwide and previous studies suggest that ILD patients experience a more severe clinical course.Objectives: To analyze COVID-19 infection effects in patients with ILD associated systemic autoinmune disease (ILD-SAI) and to describe their vaccination status. Methods: Design We performed a multicenter, retrospective, observational study from 6 teaching hospitals in Andalusia, Spain. Study protocol We included ILD-SAI patients: rheumatoid arthritis (RA), systemic sclerosis (SS) and inflammatory myopathies (IM), assisted in reumatology consultations in 2021. Variables COVID-19 infection was the main variable that we collected and it was confirmed by a positive result on a PCR test. PB BMJ Group SN 0003-4967 YR 2022 FD 2022-06-01 LK http://hdl.handle.net/10668/20074 UL http://hdl.handle.net/10668/20074 LA en NO Studer AG, Rojas-Giménez M, Feijoo MV, Romero-Barco CM, Godoy-Navarrete F, Mena-Vázquez N. AB1112 SARS-COV-2 INFECTION AND IT VACCINATION IN AUTOINMUNE DISEASE-ASSOCIATED INTERSTICIAL LUNG DISEASE. Annals Of The Rheumatic Diseases [Internet]. 23 de mayo de 2022;81(Suppl 1):1673.2-1673. DS RISalud RD Apr 20, 2025